Abstract: Objective: To assess the efficacy and safety of guselkumab in the treatment of patients with psoriatic arthritis. Methods: Randomized controlled trials (RCTs) on guselkumab for psoriatic arthritis were searched in the websites of Pubmed, Embase, Cochrane Library, CNKI, Wanfang Database and VIP datebase from inception to April 2020. The quality of articles was evaluated according to Cochrane systematic review. Two reviewers independently selected literature and extracted data. Meta analysis was performed using Revman 5.3 software. Results: A total of 3 articles were included, involving 896 patients with psoriatic arthritis (475 in the experimental group, and 421 in the control group). Meta-analysis indicated that the number of patients reached to ACR 20, ACR 70 and PASI 75, PASI 90 was more in the guselkumab group than in the placebo group at week 24.  The patients with HAQ-D1 increased by 0.35 from baseline were also higher in the guselkumab group than in the placebo group. There was no statistically significant difference in the incidence of the adverse events between the guselkumab group and the placebo group. Conclusion: Guselkumab is effective and safe in the treatment of the patients with psoriatic arthritis.

Key words: guselkumab, psoriatic arthritis, meta analysis